Go to deals
Private Equity | Healthcare

C.D.C. Complete tandzorg has sold a stake to G Square Healthcare Pte. Equity

G Square Healthcare Private Equity (G Square) has invested in C.D.C. Complete tandzorg (CDC). The partnership will enable CDC to expand its complex dental care service offering to other regions in the Netherlands by opening new practices. Financial details have not been made public.

CDC has become Netherlands’ leading dental care provider for patients who need complex treatments. CDC is specialized in the construction, placement and maintenance of dental prosthesis such as bridges and crowns, dentures, click dentures and dental implants. In addition, CDC assists patients in finding the optimal dental care solution within their insurance coverage and budget and has a special dental program for children.

G Square is a London-based, independent private equity firm, targeting mid-sized healthcare companies in Europe. G Square Capital I is the first private equity fund managed by G Square and CDC is the sixth investment.

Dr. Laurent Ganem, President and founder of G Square, said: “We are delighted to invest in CDC and look forward to working together with its highly knowledgeable and experienced management. The anesthetic center and patient-oriented approach made CDC become a thriving dental care provider with a unique market position. We are very impressed with what has been achieved so far and believe that management has the capability to successfully replicate the model to other locations in the Netherlands.”

Eric and Rob Dral, founders and managers of CDC, said: “The pan-European healthcare and especially dental care experience of G Square is very attractive for us. We believe G Square is the perfect partner and will be able to support us in our growth objectives. Holland Corporate Finance and the UK-based Cavendish Corporate Finance, played a fundamental role in identifying G Square as a buyer and realizing the transaction in a dedicated and professional manner."

Oaklins' team in the Netherlands, together with Oaklins Cavendish, based in the UK, advised the shareholders of CDC in this transaction. This deal is another example of the seamless cooperation between Oaklins' teams, demonstrating the organization’s added value through its global execution capabilities, industry expertise and contacts.

Parties

Talk to the deal team

Arjen Kostelijk

Senior Advisor
Amsterdam, Netherlands
Oaklins Netherlands

Lord Leigh of Hurley

Principal
London, United Kingdom
Oaklins Cavendish

Marc van de Put

Senior Advisor
Amsterdam, Netherlands
Oaklins Netherlands

Related deals

Bluegem Capital Partners and AREV Partners have acquired 100% of Groupe Pinard
Private Equity | Consumer & Retail | Other Industries

Bluegem Capital Partners and AREV Partners have acquired 100% of Groupe Pinard

Bluegem Capital Partners and AREV Partners have successfully completed the acquisition of the prestigious Groupe Pinard from IK Partners.

Learn more
Lumiforte partners with Kartesia to propel global growth and innovation
Private Equity | Agriculture | Other Industries

Lumiforte partners with Kartesia to propel global growth and innovation

Lumiforte, a global leader in innovative smart coatings for greenhouse horticulture, sports line-marking and other functional coatings for agriculture and industry, is excited to announce an investment from Kartesia, a European specialist in capital solutions for small and medium-sized companies. Horticoop, a longstanding shareholder of Lumiforte and a key player in the horticultural industry through its investment cooperative, continues to remain a shareholder.

Learn more
PanTera secures US$104.1 million in oversubscribed Series A round to accelerate global actinium-225 production
Healthcare

PanTera secures US$104.1 million in oversubscribed Series A round to accelerate global actinium-225 production

PanTera, a Belgian radioisotope producer, has completed a US$104.1 million (€93 million) oversubscribed Series A fundraising round led by EQT Life Sciences. Additional equity and debt funding brings the total amount raised to US$150 million (€134 million). In addition to EQT Life Sciences, the Series A round was also joined by Kurma Partners, Eurazeo, Korys, Paladin and PMV.

Learn more